Research firm KLAS released a new report on electronic medical record (EMR) usability and product performance over the past two years, revealing how physicians and other users rate various vendors and solutions. The report, entitled “Physician Leadership Weighs In on Acute Care EMR Usability” compares usability performance in the acute care EMR market segment.

Results from Lantheus Medical Imaging Inc.’s first Phase 3 study of flurpiridaz F 18 for myocardial perfusion imaging (MPI) were presented at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC12) in Madrid, Spain. The oral presentation was made by Jamshid Maddahi, M.D., professor of medicine (cardiology) and molecular & medical pharmacology (nuclear medicine), David Geffen School of Medicine at UCLA, in the “Important Clinical Trials and Registries in Nuclear Cardiology” session of ICNC12.


A large-scale, multicenter study has shown that therapeutic hypothermia does not improve survival rates or reduce brain injury in infants and children with out-of-hospital cardiac arrest more than normal temperature control.


Thoratec Corp. announced results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory New York Heart Association (NYHA) Class IIIB/IV (INTERMACS profile 4-7) heart failure patients. One-year study results were presented during the 35th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT 2015) in Nice, France.

Boston Scientific Corp. is taking a new approach to evaluate the performance of the Vessix Renal Denervation System, initiating a study to isolate the effects of the therapy in patients with high blood pressure.

Sunshine Heart Inc. announced that the U.S. Food and Drug Administration (FDA) has reviewed the company’s submission regarding the pause of the COUNTER HF U.S. pivotal study. The FDA has requested minor protocol changes be submitted in order to receive approval to resume patient enrollment.

There have been several technology advances in PET/CT (positron emission tomography/computed tomography) systems recently introduced by vendors. On the show floors of the 2014 Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting and the 2014 Radiological Society of North America (RSNA) meeting, Philips, Toshiba and GE Healthcare introduced new PET/CT systems.



It’s the invisible elephant in radiology — radiation exposure. As physicians, we know all too well that exposure to radiation should be limited to the least amount possible. We have all learned about the ALARA principle for keeping exposure low. We also take precautions on our patients’ behalf and educate them. But what about us? The physicians and technical staff who treat patients every day cannot avoid radiation exposure entirely. However, there is growing evidence that not only is radiation exposure detrimental to our health, but also many long-term cumulative effects are still unknown.


Based on its ongoing analysis of the medical imaging market, Frost & Sullivan recognizes Toshiba America Medical Systems, Inc. with the 2015 North American Frost & Sullivan Award for Medical Imaging Company of the Year. The company has changed the way it approaches the imaging market by offering scalable, upgradable technologies and a patient-focused view of partnerships. This value-based approach positions the company for continued success in the medical imaging market by allowing it to re-orient many of its imaging customers away from a cyclical sales model and toward deeper, more renewable strategic partnerships.

Subscribe Now